Logo image of ADAP

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Fundamental Analysis

NASDAQ:ADAP - Nasdaq - US00653A1079 - ADR - Currency: USD

0.5595  -0.02 (-3.45%)

After market: 0.5619 +0 (+0.43%)

Fundamental Rating

2

Taking everything into account, ADAP scores 2 out of 10 in our fundamental rating. ADAP was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ADAP have multiple concerns. While showing a medium growth rate, ADAP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADAP had negative earnings in the past year.
ADAP had a negative operating cash flow in the past year.
ADAP had negative earnings in each of the past 5 years.
ADAP had negative operating cash flow in 4 of the past 5 years.
ADAP Yearly Net Income VS EBIT VS OCF VS FCFADAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

ADAP has a Return On Assets of -14.02%. This is amongst the best in the industry. ADAP outperforms 85.26% of its industry peers.
Looking at the Return On Equity, with a value of -55.65%, ADAP is in the better half of the industry, outperforming 62.17% of the companies in the same industry.
Industry RankSector Rank
ROA -14.02%
ROE -55.65%
ROIC N/A
ROA(3y)-41.42%
ROA(5y)-45.74%
ROE(3y)-188.98%
ROE(5y)-143.21%
ROIC(3y)N/A
ROIC(5y)N/A
ADAP Yearly ROA, ROE, ROICADAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADAP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAP Yearly Profit, Operating, Gross MarginsADAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADAP has more shares outstanding
Compared to 5 years ago, ADAP has more shares outstanding
ADAP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADAP Yearly Shares OutstandingADAP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
ADAP Yearly Total Debt VS Total AssetsADAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

ADAP has an Altman-Z score of -3.29. This is a bad value and indicates that ADAP is not financially healthy and even has some risk of bankruptcy.
ADAP has a Altman-Z score (-3.29) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.62 indicates that ADAP is somewhat dependend on debt financing.
The Debt to Equity ratio of ADAP (0.62) is worse than 77.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -3.29
ROIC/WACCN/A
WACC9.05%
ADAP Yearly LT Debt VS Equity VS FCFADAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

ADAP has a Current Ratio of 3.85. This indicates that ADAP is financially healthy and has no problem in meeting its short term obligations.
ADAP has a Current ratio (3.85) which is in line with its industry peers.
A Quick Ratio of 3.82 indicates that ADAP has no problem at all paying its short term obligations.
ADAP's Quick ratio of 3.82 is in line compared to the rest of the industry. ADAP outperforms 46.89% of its industry peers.
Industry RankSector Rank
Current Ratio 3.85
Quick Ratio 3.82
ADAP Yearly Current Assets VS Current LiabilitesADAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.54% over the past year.
Looking at the last year, ADAP shows a very strong growth in Revenue. The Revenue has grown by 146.26%.
Measured over the past years, ADAP shows a small growth in Revenue. The Revenue has been growing by 0.26% on average per year.
EPS 1Y (TTM)68.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
Revenue 1Y (TTM)146.26%
Revenue growth 3Y147.83%
Revenue growth 5Y0.26%
Sales Q2Q%458.83%

3.2 Future

ADAP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.81% yearly.
The Revenue is expected to grow by 22.91% on average over the next years. This is a very strong growth
EPS Next Y80.64%
EPS Next 2Y19.74%
EPS Next 3Y13.77%
EPS Next 5Y1.81%
Revenue Next Year123.73%
Revenue Next 2Y-30.12%
Revenue Next 3Y-8.5%
Revenue Next 5Y22.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADAP Yearly Revenue VS EstimatesADAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ADAP Yearly EPS VS EstimatesADAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADAP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAP Price Earnings VS Forward Price EarningsADAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAP Per share dataADAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ADAP's earnings are expected to grow with 13.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.74%
EPS Next 3Y13.77%

More info and screens

0

5. Dividend

5.1 Amount

ADAP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (2/21/2025, 8:00:00 PM)

After market: 0.5619 +0 (+0.43%)

0.5595

-0.02 (-3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners49.87%
Inst Owner Change-99.86%
Ins Owners0.21%
Ins Owner Change-0.16%
Market Cap143.17M
Analysts77.33
Price Target2.31 (312.87%)
Short Float %16.18%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)260.34%
Min EPS beat(2)92.37%
Max EPS beat(2)428.3%
EPS beat(4)2
Avg EPS beat(4)76.33%
Min EPS beat(4)-135.29%
Max EPS beat(4)428.3%
EPS beat(8)4
Avg EPS beat(8)40.79%
EPS beat(12)5
Avg EPS beat(12)1.24%
EPS beat(16)7
Avg EPS beat(16)0.77%
Revenue beat(2)2
Avg Revenue beat(2)218.16%
Min Revenue beat(2)177.41%
Max Revenue beat(2)258.91%
Revenue beat(4)2
Avg Revenue beat(4)74.51%
Min Revenue beat(4)-98.89%
Max Revenue beat(4)258.91%
Revenue beat(8)4
Avg Revenue beat(8)154.26%
Revenue beat(12)6
Avg Revenue beat(12)100.06%
Revenue beat(16)7
Avg Revenue beat(16)75.48%
PT rev (1m)0%
PT rev (3m)-11.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.84%
EPS NY rev (1m)21.25%
EPS NY rev (3m)67.69%
Revenue NQ rev (1m)-1.16%
Revenue NQ rev (3m)-61.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.82
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.89
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.68
BVpS0.31
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.02%
ROE -55.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.42%
ROA(5y)-45.74%
ROE(3y)-188.98%
ROE(5y)-143.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.11%
Cap/Sales 1.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.85
Quick Ratio 3.82
Altman-Z -3.29
F-Score4
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)224.13%
Cap/Depr(5y)149.8%
Cap/Sales(3y)86.8%
Cap/Sales(5y)121.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
EPS Next Y80.64%
EPS Next 2Y19.74%
EPS Next 3Y13.77%
EPS Next 5Y1.81%
Revenue 1Y (TTM)146.26%
Revenue growth 3Y147.83%
Revenue growth 5Y0.26%
Sales Q2Q%458.83%
Revenue Next Year123.73%
Revenue Next 2Y-30.12%
Revenue Next 3Y-8.5%
Revenue Next 5Y22.91%
EBIT growth 1Y67.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-443.34%
OCF growth 3YN/A
OCF growth 5YN/A